subunit vaccine


Also found in: Dictionary, Thesaurus, Medical.

subunit vaccine

[‚səb‚yü·nit vak′sēn]
(immunology)
A type of noninfectious vaccine that consists of immunogenic viral proteins stripped free from whole virus particles, then purified from other irrelevant components, thereby reducing the risk of adverse reactions and residual infectious virus.
Mentioned in ?
References in periodicals archive ?
A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge.
In comparison with live attenuated candidates, safety compliance requirements for potential licensure are expected to be easier to achieve with subunit vaccines. However, overcoming efficacy limitations of subunit candidates has been the challenge to date.
Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
Our group has been studying the possible use of antioxidant proteins of Leishmania as possible subunit vaccine candidates in the form of recombinant protein and/or DNA.
AAV-4 Isolate showed 26 epitopes, Hypervariable region of hexon gene was predicted as a subunit vaccine candidate using Vaxijen server showing it as probable antigen.
Astragalus extracted as vaccine adjuvant significantly improves immune activity of E0 subunit vaccine. As such, the plant-made glycoprotein E0 has the ability to generate an immune response in sika deer.
Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: Results of the initial evaluation in children.
In addition it confirms the versatility of our subunit vaccine technology platform," Parks notes.
Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein b subunit vaccine. J Infect Dis 1999; 180: 1700-3.
Subunit vaccine based on the p67 major surface protein of Theileria parva sporozoites reduces severity of infection derived from field tick challenge.
The most advanced subunit vaccine is being developed by Hawaii Biotech Inc., and is based on the envelope (E) protein produced in the Drosophila S2 expression system, whereby glycosylation is maintained and immunoaffinity purified, in order to achieve conformational folding.
1981 ARS develops foot-and-mouth disease vaccine--the first effective subunit vaccine for any animal or human disease using gene splicing.